A clinical trial of the effect of yogurt containing Lactobacillus gasseri (LG2055) on postprandial triglyceride, nonesterified fatty acids and glucose metabolism

A clinical trial of the effect of yogurt containing Lactobacillus gasseri (LG2055) on postprandial triglyceride, nonesterified fatty acids and glucose metabolism - A clinical trial of the effect of Lactobacillus gasseri (LG2055) on postprandial triglyceride and nonesterified fatty acids metabolism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011605

Enrollment

Registered

2013-08-30

Start date

2011-11-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipidemia

Interventions

200g/day for 4 weeks twice a day, 100g each after breakfast and dinner intake of placebo yogurt for 4 weeks -&gt

washout period for 4 weeks -&gt

intake of yogurt containing Lactobacillus gassreri (LG2055) for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)TypeIIb or typeIV hyperlipoproteinemia in NCEP ATPIII(fasting serum triglyceride level >=200 mg/dL) 2)Normal blood glucose level(fasting blood glucose level<110 mg/dL) 3)Nonsmoker 4)Subject, upon briefing of the content of the present study, fully understands and agrees to its objective and is able to personally give written informed consent

Exclusion criteria

Exclusion criteria: 1)Subject having treatment or previous history for serious cardiovascular, respiratory, endocrine, or metabolic disorders 2)Subject having coronary heart disease, renal disorder, hypothyroidism, liver disorder 3)Subject taking medicine for promoting excretion from stomach, lipoprotein metabolism, insulin secretion and insuline activation 4)Subject being on a diet therapy 5)Subject taking FOSHU for decreasing serum triglyceride level, body fat or blood glucose level 6)Subject who ended participation in another clinical trial less than 3 months before and who is currently involved in another clinical trial 7)Subject having a food allergy, especially dairy products 8)For female subjects: pregnancy or possibility of pregnancy, or intending to become pregnant during the study. 9) Subject who has had a blood sample of 200 ml or more taken (e.g., donated blood) within 1 month, or 400 ml or more within 3 months of the start of the present study. 10) Subject deemed unsuitable by the investigator.

Design outcomes

Primary

Measure	Time frame
Serum triglyceride and nonesterified fatty acid levels in lipid and glucose absorption test after 4-week intake	—

Secondary

Measure	Time frame
Blood glucose level in lipid and glucose absorption test after 4-week intake	—

Countries

Japan

Contacts

Public ContactSugino Tomohiro

Soiken Inc. R&D division

sugino@soiken.com06-6871-8888

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026